as of 12-15-2025 11:21am EST
Inovio Pharmaceuticals Inc is a United States-based biotechnology company. The company is focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
| Founded: | 1979 | Country: | United States |
| Employees: | N/A | City: | PLYMOUTH MEETING |
| Market Cap: | 136.6M | IPO Year: | 1998 |
| Target Price: | $9.00 | AVG Volume (30 days): | 1.1M |
| Analyst Decision: | Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.78 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.30 - $4.08 | Next Earning Date: | 11-10-2025 |
| Revenue: | $182,337 | Revenue Growth: | -10.36% |
| Revenue Growth (this year): | -61.15% | Revenue Growth (next year): | 21219.94% |
Machine learning model trained on 25+ technical indicators
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
See how INO stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "INO Inovio Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.